Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3.0 mg) reduce energy intake by 34.5% and 13.0% respectively, leading to estimated body weight reductions of 17% and 8% at 20 weeks.
Clinical doses of GLP-1 agonists (semaglutide 2.4mg, liraglutide 3.0mg) significantly reduce energy intake, leading to substantial weight loss (8-17%) over 20 weeks. This effect is primarily driven by reduced food intake rather than just increased energy expenditure, and the model accounts for diminishing efficacy (tolerance) over time.
The estimated reduction in EI of clinically relevant dosages of semaglutide (2.4 mg) and liraglutide (3.0 mg) was 34.5% and 13.0%, respectively... At 20 weeks the change in BW was estimated to be −17% for 2.4 mg semaglutide and −8% for 3 mg liraglutide, respectively.
Why this rating
Based on a quantitative systems pharmacology model validated against multiple clinical trials (liraglutide and semaglutide), though it is a modeling study rather than a new primary clinical trial.
Source
Quantification of the effect of <scp>GLP</scp>‐<scp>1R</scp> agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model
Rolien Bosch et al. · CPT Pharmacometrics & Systems Pharmacology · 2024
DOI 10.1002/psp4.13183
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →